Conceptus, Inc. Logo

Conceptus(R) to Participate in Four Investor Conferences

| Source: Conceptus, Inc.

MOUNTAIN VIEW, Calif., May 9, 2012 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure® procedure, the first and only proven non-incisional permanent birth control method available, announced today that company management is planning to participate in the following investor conferences:

  • The Bank of America Merrill Lynch 2012 Health Care Conference on Tuesday, May 15, 2012, in Las Vegas, Nevada. A live webcast of the company presentation will take place at 8:40 a.m. Pacific time and will be available on the company's website at
  • The GARP Research and Securities Company Investor Conference on Wednesday, May 23, 2012, in Baltimore, Maryland. There will be no webcast presentation.
  • The 9th Annual Craig-Hallum Institutional Investor Conference on Wednesday, May 30, 2012, in Minneapolis, Minnesota. There will be no webcast presentation.
  • The Jefferies 2012 Global Healthcare Conference on Tuesday, June 5, 2012, in New York City, New York.  A live webcast of the company presentation will take place at 8:00 a.m. Eastern time and will be available on the company's website at

When accessing the live webcasts on, select "Investors" then select "Events and Presentations." Archived replays will be available following the live presentations.

About the Essure® Procedure

The Essure procedure, FDA approved since 2002, is the first permanent birth control method that can be performed in the comfort of a physician's office in less than 10 minutes (average hysteroscopic time) without hormones, cutting, burning or the risks associated with general anesthesia or tubal ligation. Soft, flexible inserts are placed in a woman's fallopian tubes through the cervix without incisions. Over the next three months, the body forms a natural barrier around and through the inserts to prevent sperm from reaching the egg. Three months after the Essure procedure, a doctor is able to perform an Essure Confirmation Test to confirm that the inserts are properly placed and that the fallopian tubes are fully blocked, allowing the patient to rely upon Essure for permanent birth control.

The Essure procedure is 99.83% effective based on five years of follow up with zero pregnancies reported in clinical trials, making it the most effective form of permanent birth control on the market. Essure's 10-year commercial data tracks closely with its five-year clinical results, and Essure has been proven and trusted by physicians since 2002. The Essure procedure is covered in the U.S. by most public and private insurance plans and more than 625,000 women worldwide have undergone the procedure.  

About Conceptus®, Inc.

Conceptus, Inc. is a leader in the design, development and marketing of innovative solutions in women's healthcare. The Company manufactures and markets the Essure procedure. The Essure procedure is available in the United States, Europe, Australia, New Zealand, Canada, Mexico, Central and South America and the Middle East. 

Please visit for more information on the Essure procedure. Patients may call the Essure Information Center at 1-877-ESSURE-1 with questions or to find a physician in their area.

The Conceptus, Inc. logo is available at

© 2012 Conceptus, Inc.— All rights reserved.

Investor and Public Relations Contact:
Cindy Klimstra
(650) 962-4032